Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Editors in Chief

Authors

Staff

Additional Disclosure Information

The following staff have previously contributed to the content of this module and disclosed the following potential conflicts of interest:

Kathleen E. Squires, MD, disclosed that she had served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV; had served on advisory boards for marketing purposes for Gilead Sciences and Janssen; had served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Koronis, Pfizer, Schering-Plough, Tibotec, and Tobira; had received funds for research support from BioCryst, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Koronis, Merck, Schering-Plough, Tibotec, and Vertex; and had received consulting fees from GlaxoSmithKline and Merck at the time she contributed to this module.

Paul E. Sax, MD, disclosed that he had received consulting fees from Abbott, Aileron, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Pfizer, and ViiV and funds for research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Tibotec/Janssen at the time he contributed to this module.

Steve McGuire, Anna Poppa, and Elaine P. Seeskin had no real or apparent conflicts of interest to report at the time they contributed to this module.

Kimberly Y. Smith, MD, MPH, disclosed that she had served on advisory boards and as a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and ViiV and had participated in speaker bureaus for GlaxoSmithKline and Merck at the time she contributed to this module.

Disclaimer

The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Contact Information

If you have technical queries about using this site, please contact: techhelp@clinicaloptions.com.

If you have credit related queries or a complaint, please contact: skelley@clinicaloptions.com.

inPractice Hepatology current certification period
Release Date: January 1, 2019
Expiration Date: June 30, 2019

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with viral hepatitis.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of viral hepatitis.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

• Epidemiology and prevention: Evaluate current demographic trends in viral hepatitis, modes of sexual and nonsexual transmission of viral hepatitis, and guidelines for implementing viral hepatitis testing, prevention, and infection control
• Basic science: Interpret the clinical significance of natural history, disease pathogenesis, and factors associated with disease progression in patients with viral hepatitis
• Clinical management: Integrate appropriate methods of detection and diagnosis, patient history taking, syndromic evaluation for differential diagnosis, and health maintenance interventions into patient care in individuals with viral hepatitis; appraise the importance of diverse aspects of patient care including issues in specific patient populations and coordination of care
• Initial therapy for hepatitis B: Formulate state-of-the-art antiviral management strategies for treatment-naive patients with hepatitis B, including attention to considerations when selecting regimens, monitoring, and goals of therapy
• Initial therapy for hepatitis C: Apply state-of-the-art antiviral management strategies for treatment-naive patients with hepatitis C, including attention to considerations when selecting regimens, monitoring, goals of therapy, and use of response-guided treatment strategies
• Treatment-experienced hepatitis C patients: Optimally manage treatment-experienced patients, including setting appropriate goals of therapy, optimizing patient adherence, minimizing adverse events, and selecting optimal therapy, including dose and duration
• Antiviral resistance in hepatitis B: Mitigate the clinical impact of antiviral resistance, including resistance assays and their interpretation, patterns of emergent drug resistance associated with different regimens, and management of patients with resistance

Commercial Support

This program is supported by educational grants from AbbVie and Gilead Sciences.

inPractice HIV current certification period
Release Date: September 26, 2019
Expiration Date: September 25, 2020

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the management of patients with HIV.

Goal:

The goal of this activity is to provide a comprehensive clinical reference resource on the prevention, diagnosis, and treatment of HIV disease.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

• Demonstrate an improvement in patient outcomes by applying information at the point of care
• Epidemiology and prevention: evaluate current demographic trends in HIV disease, modes of sexual and nonsexual transmission of HIV, and Centers for Disease Control and Prevention guidelines for implementing HIV testing, prevention, and infection control
• HIV-related basic science: Interpret the clinical significance of the HIV life cycle and natural history, virologic and immunologic aspects of disease pathogenesis, and factors associated with disease progression
• Clinical management: Integrate methods of HIV detection and diagnosis, patient history taking, syndromic evaluation for differential diagnosis, and health maintenance interventions into patient care; apply best practices in diverse aspects of patient care including issues in specific patient populations and coordination of care
• Disease manifestations: Manage the clinical presentation, diagnosis, treatment, and prophylaxis for the full range of opportunistic diseases, coinfections, and HIV-associated disorders that may occur in HIV-infected patients
• Initial antiretroviral therapy: Formulate state-of-the-art antiretroviral management strategies for treatment-naive patients, including attention to considerations when selecting regimens, monitoring and goals of therapy, and strategies for maximizing adherence
• Antiretroviral resistance: Appraise the clinical impact of antiretroviral resistance, including resistance assays and their interpretation, transmitted resistance, and patterns of emergent drug resistance associated with different regimens
• Treatment-experienced patients: Optimally manage treatment-experienced patients, including setting appropriate goals of therapy and selecting active agents when constructing new regimens
• Complications of antiretroviral therapy: Manage common antiretroviral toxicities and drug-drug interactions among antiretroviral agents and among antiretrovirals and concomitant agents

Commercial Support:

This program is supported by educational grants from Gilead Sciences and ViiV Healthcare.

For inPractice Hepatology

Physician Continuing Medical Education (for Point of Care CME activities)

For inPractice HIV

Physician Continuing Medical Education (for Point of Care CME activities)